S. Bortini

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
A phase I study was performed with MEN-10755, a novel anthracycline with promising preclinical antitumour activity, in patients with solid tumours to determine the maximum tolerated dose (MTD); the(More)
  • 1